ETANERCEPT IN THE REAL CLINICAL PRACTICE OF TREATMENT IN PATIENTS WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.14412/1995-4484-2013-1200
Abstract
The paper presents the results of an open-label nonrandomized prospective trial, the purpose of which was to evaluate the efficiency and safety of etanercept (ETC) treatment for different forms and variants of active juvenile idiopathic arthritis (JIA) in real clinical practice. The trial included 24 patients with JIA. ETC treatment proved to be effective in most patients with a long disease history and a high clinical and laboratory activity who were refractory to conventional antirheumatic therapy. ETC therapy was most effective in patients with the articular form of the disease who showed 100% improvement in at least ACRpedi30 criteria at 6 months of treatment.
About the Authors
Elena Spartakovna Zholobova
Университетская детская клиническая больница Первого МГМУ им. И.М. Сеченова, Москва
O Yu Konopelko
Университетская детская клиническая больница Первого МГМУ им. И.М. Сеченова, Москва
O S Rozvadovskaya
Университетская детская клиническая больница Первого МГМУ им. И.М. Сеченова, Москва
V Ya Elyashevich
Университетская детская клиническая больница Первого МГМУ им. И.М. Сеченова, Москва
M N Nikolayeva
Университетская детская клиническая больница Первого МГМУ им. И.М. Сеченова, Москва
References
1. <div><p>Бзарова Т.М., Алексеева Е.И., Васильева С.И. и др. Безопасность применения ингибиторов факторов некроза опухоли альфа во взрослой и детской ревматологической практике. Вопр совр педиатр 2010;9(1):2—15.</p><p>Жолобова Е.С., Чебышева С.Н., Геппе Н.А. и др. Клиникорентгенологическая динамика у пациента с системной формой ювенильного ревматоидного артрита на терапии этанерцептом. Леч врач 2011;4:83-5.</p><p>Никишина И.П. Растворимые рецепторы к фактору некроза опухоли (этанерцепт) в терапии ювенильного артрита. Рус мед журн 2009;17(3):2-7.</p><p>Beutler B.A. The role of tumor necrosis factor in health and disease. J Rheumatol 1999;57(Suppl):16—21.</p><p>Lovell D.J., Giannini E.H., Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342(11):763-9.</p><p>Kietz D.A., Pepmueller P.H., Moore T.L. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 2001;28:360-2.</p><p>Otten M., Prince F., Twilt M. et al. Delaed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2010;37:665-7.</p><p>Lovell D.J., Giannini E.H., Reiff A. et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthr Rheum 2003;48:218-26.</p><p>Lovell D.J., Reiff A., Jones O.Y. et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthr Rheum 2006;54:1987-94.</p><p>Lovell D.J., Reiff A., Ilowite N.T. et al. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis. Arthr Rheum 2008;58(5):1496-504.</p></div><br />
Review
For citations:
Zholobova E.S., Konopelko O.Yu., Rozvadovskaya O.S., Elyashevich V.Ya., Nikolayeva M.N. ETANERCEPT IN THE REAL CLINICAL PRACTICE OF TREATMENT IN PATIENTS WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS. Rheumatology Science and Practice. 2013;51(1):44-47. (In Russ.) https://doi.org/10.14412/1995-4484-2013-1200
Views:
909
Email this article 